A pivotal randomized, controlled, multi-center study of LJPC-401 in beta thalassemia patients suffering from iron overload
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Hepcidin (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- 01 Mar 2017 Planned initiation date changed to 1 Jun 2017.
- 22 Sep 2016 New trial record
- 07 Sep 2016 According to a La Jolla Pharmaceutical Company media release, the company has reached agreement with the European Medicines Agency (EMA) on the design of this pivotal study of LJPC-401.